Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Clin Case Rep ; 5(5): 555-558, 2017 05.
Artigo em Inglês | MEDLINE | ID: mdl-28469848

RESUMO

Diffuse large B-cell lymphoma (DLBCL) can involve the esophagus from local spread, distant metastasis and very rarely can also be the primary site. Once DLBCL is diagnosed, caution should be exercised in further evaluation for local treatments of sites like adnexal masses as was seen in this case; sometimes it is DLBCL at atypical sites.

2.
Leuk Lymphoma ; 55(12): 2850-7, 2014 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-24588734

RESUMO

This study analyzed the survival of patients with multiple myeloma. Surveillance, Epidemiology, and End Results (SEER) and Centers for Disease Control and Prevention (CDC) databases were queried to calculate myeloma cause-specific survival curves by the Kaplan and Meier product-limit method. The Cox proportional hazards model was used to assess univariate and multivariate predictors of myeloma cause-specific survival. The outcome of interest was death due to myeloma. Results from a Cox proportional hazards model restricted to age and time period at diagnosis demonstrated that the magnitude of improvement in survival by time period varied by age at diagnosis. Among patients under 60 years at diagnosis, hazard ratios for myeloma cause-specific death decreased by more 50% from the first interval of observation to the last. Hazard ratios decreased during the study period by 39% among patients 60-69 years of age and by 27% among patients who were 70 years of age and older. Survival is improving in patients with myeloma of all ages.


Assuntos
Mieloma Múltiplo/mortalidade , Idoso , Idoso de 80 Anos ou mais , Feminino , História do Século XX , História do Século XXI , Humanos , Incidência , Masculino , Pessoa de Meia-Idade , Mieloma Múltiplo/epidemiologia , Mieloma Múltiplo/história , Prognóstico , Programa de SEER , Estados Unidos/epidemiologia , Estados Unidos/etnologia
3.
Breast Cancer Res Treat ; 132(2): 355-63, 2012 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-21987034

RESUMO

Breast cancer is the second most common cancer among American women and has a high rate of metastasis to bone. Patients regularly undergo adjuvant therapy (chemotherapy or hormonal therapy) following surgical resection of the tumor. In addition to potential direct effects on bone cells, both chemotherapy and hormonal therapy induce ovarian dysfunction and dramatically decrease estrogen levels in both pre- and postmenopausal women. This leads to decreased bone mineral density and increased fracture risk. Antiresorptive therapies (e.g, zoledronic acid and denosumab) have demonstrated efficacy in preventing cancer therapy-induced bone loss in patients with breast cancer and are approved for the prevention of skeletal-related events in patients with bone metastases from breast cancer. This review will focus on the evolving role of these antiresorptive therapies in the care of women with early or metastatic breast cancer.


Assuntos
Antineoplásicos Hormonais/efeitos adversos , Conservadores da Densidade Óssea/uso terapêutico , Neoplasias Ósseas/tratamento farmacológico , Reabsorção Óssea/prevenção & controle , Neoplasias da Mama/tratamento farmacológico , Fraturas Ósseas/prevenção & controle , Osteoporose/prevenção & controle , Animais , Densidade Óssea/efeitos dos fármacos , Conservadores da Densidade Óssea/efeitos adversos , Neoplasias Ósseas/complicações , Neoplasias Ósseas/secundário , Reabsorção Óssea/etiologia , Reabsorção Óssea/patologia , Neoplasias da Mama/complicações , Neoplasias da Mama/patologia , Quimioterapia Adjuvante , Feminino , Fraturas Ósseas/etiologia , Fraturas Ósseas/patologia , Humanos , Osteoporose/etiologia , Osteoporose/patologia , Fatores de Risco , Resultado do Tratamento
4.
Semin Hematol ; 48(4): 259-63, 2011 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-22000091

RESUMO

The association between venous thromboembolism (VTE) and malignancy is well established. Recent interest has focused on standards of care for prophylaxis, diagnosis, and treatment of malignancy-associated thrombosis. Anticoagulant management in cancer patients has unique complexities such as prolonged hospitalization, extensive surgeries, extended periods of inactivity, indwelling central venous catheters (CVC), thrombocytopenia, and pro-thrombotic medications. Here we will explore current recommendations for various specific clinical scenarios for cancer-associated thromboses. We will make evidence-based recommendations wherever possible; however, several of the scenarios here were included because pertinent high-quality evidence does not exist.


Assuntos
Neoplasias/complicações , Tromboembolia Venosa/complicações , Trombose Venosa/complicações , Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Neoplasias/sangue , Neoplasias/tratamento farmacológico , Fatores de Risco , Tromboembolia Venosa/tratamento farmacológico , Trombose Venosa/tratamento farmacológico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...